TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3514487

Group type: EXPERIMENTAL
Intervention: 50 mg atenolol
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 12.5 mg chlorthalidone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of 50 mg atenolol and 12.5 mg chlorthalidone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of atenolol-chlorthalidone
Number of subjects: 28
Study: 31882408

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment
Number of subjects: 0
Study: 29972391

Group type: EXPERIMENTAL
Intervention: Positive pressure group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inspiratory load group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study: 27190356

Group type: EXPERIMENTAL
Intervention: Frequent in-center hemodialysis (6 times per week)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Frequent nocturnal home hemodialysis (6 times per week)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Conventional hemodialysis (3 times per week)
Number of subjects: 332
Study: 24472759

Group type: EXPERIMENTAL
Intervention: Pain and gallbladder descriptors, psychosocial/functional disorder questionnaires
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Narcotics usage
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Demographic factors, gallbladder pathology, increased pancreatobiliary enzymes, functional disorders, and pain patterns
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Anxiety and depression
Number of subjects: 214
Study: 23212058

Group type: EXPERIMENTAL
Intervention: L-methylfolate (15 mg/day)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: L-methylfolate (7.5 mg/day for 30 days followed by 15 mg/day for 30 days)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo (for 30 days followed by L-methylfolate 7.5 mg/day for 30 days)
Number of subjects: 223
Study: 20642249

Group type: EXPERIMENTAL
Intervention: Fentanyl iontophoretic transdermal system (ITS)
Number of subjects: 1288
Study: 21858581

Group type: EXPERIMENTAL
Intervention: Forward-training group
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Reverse-training group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 22
Study: 15679718

Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microg
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Ciclesonide 640 microg
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study: 12895452

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients
Number of subjects: 22
Study: 9863872

Group type: EXPERIMENTAL
Intervention: Dideoxynucleoside monotherapy (zidovudine)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combination therapy (zidovudine, zalcitabine, didanosine)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Overall adherence
Number of subjects: 41
Study: 7897523

Group type: EXPERIMENTAL
Intervention: 8 drugs in 1 day regimen followed by high-dose methotrexate (12 g/m2)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Postirradiation chemotherapy with four 8/1 courses monthly
Number of subjects: 68

Group type: COMPARATOR
Intervention: Comparison of radiation doses in Group B
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Overall treatment including sandwich chemotherapy
Number of subjects: 68
Study: 2495900

Group type: EXPERIMENTAL
Intervention: 1 mg sodium cromoglycate metered dose inhaler
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 5 mg sodium cromoglycate metered dose inhaler
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 139
Study: 799981

Group type: EXPERIMENTAL
Intervention: New analgesic compound (propoxyphene, acetaminophen, caffeine, hydroxyzine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plain acetaminophen
Number of subjects: 40
Study: 30599803

Group type: EXPERIMENTAL
Intervention: Dual-task walking
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normal walking
Number of subjects: 70
Study: 27403608

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified corn-soy blend
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified LNS with milk protein base
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified LNS with soy protein base
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (no supplementary food)
Number of subjects: 4
Study: 26273669

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 1167
Study: 23062314

Group type: EXPERIMENTAL
Intervention: Widened spatial QRS-T angle
Number of subjects: 4453

Group type: COMPARATOR
Intervention: Normal spatial QRS-T angle
Number of subjects: 4453
Study: 21609640

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Combined oral contraceptives (COC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both LNG-IUS and COC
Number of subjects: 48
Study: 18840113

Group type: EXPERIMENTAL
Intervention: Light sedation (MAAS 3-4)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Heavy sedation (MAAS 1-2)
Number of subjects: 36
Study: 16511927

Group type: EXPERIMENTAL
Intervention: Multidisciplinary clinical management approach (experimental group)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Reference treatment approach (control group)
Number of subjects: 288
Study: 12930331

Group type: EXPERIMENTAL
Intervention: PDL-CSC
Number of subjects: 35

Group type: COMPARATOR
Intervention: PDL alone
Number of subjects: 35
Study: 10710841

Group type: EXPERIMENTAL
Intervention: Contingent incentives based on cocaine-free urinalysis results
Number of subjects: 70

Group type: COMPARATOR
Intervention: Noncontingent incentives (independent of urinalysis results)
Number of subjects: 70
Study: 8939038

Group type: EXPERIMENTAL
Intervention: Imitation of faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions (concentration on faces)
Number of subjects: 0
Study: 1608327

Group type: EXPERIMENTAL
Intervention: Teaching intervention of basic technical skills
Number of subjects: 25
Study: 3899166

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 0
Study: 28813701

Group type: EXPERIMENTAL
Intervention: Knowledge of cervical length (CL) provided to the study group; CL measurement performed 24‐48 h after admission. If CL was >25 mm, early discharge within 12‐24 h from randomization was recommended.
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (blinded to CL measurement).
Number of subjects: 149
Study: 27635609

Group type: EXPERIMENTAL
Intervention: Cytoflavin (20 ml per 400 ml of 5% glucose solution, intravenously, 1 time a day for 10 days, then 2 tablets 2 times a day for a month)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 52
Study: 23899830

Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.45 mg
Number of subjects: 2177

Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.625 mg
Number of subjects: 2177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2177
Study: 23350203

Group type: EXPERIMENTAL
Intervention: Lipoid + Aronia extract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipoid + Larix extract + Hibiscus extract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipoid + Silybum extract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipoid + Q10 + Rosa majalis extract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aronia + Raponticum extracts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Larix + Hibiscus extracts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schizandra + Aronia extracts
Number of subjects: 0
Study: 20429751

Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI) in dementia patients with frontal lobe symptoms
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (10 Alzheimer patients without frontal lobe symptoms and 10 normal controls, N=20)
Number of subjects: 23
Study: 18534620

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 456

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 456
Study: 16188154

Group type: EXPERIMENTAL
Intervention: Concurrent radio-chemotherapy (NVB + DDP plus radiotherapy)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional chemotherapy (NVB + DDP)
Number of subjects: 64
Study: 12358338

Group type: EXPERIMENTAL
Intervention: Nedocromil (two puffs of 2 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Salbutamol (two puffs of 100 microg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combination of nedocromil and salbutamol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 10425589

Group type: EXPERIMENTAL
Intervention: TransCyte
Number of subjects: 32

Group type: COMPARATOR
Intervention: Silver sulfadiazine
Number of subjects: 32
Study: 7574126

Group type: EXPERIMENTAL
Intervention: Simplified discharge instructions
Number of subjects: 423

Group type: COMPARATOR
Intervention: Standard discharge instructions
Number of subjects: 423
Study: 2176235

Group type: EXPERIMENTAL
Intervention: Enoxaparin 20 mg twice (group A)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once (group B)
Number of subjects: 103
Study: 7000106

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS) 12.5 mg kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS) 25 mg kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oxycodone 0.15 mg kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS)
Number of subjects: 60
Study: 31715047

Group type: EXPERIMENTAL
Intervention: Pre-race ECG
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Post-race ECG
Number of subjects: 301
Study: 30370450

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU) after memory retrieval
Number of subjects: 61

Group type: COMPARATOR
Intervention: Intranasal oxytocin (40 IU) without retrieval
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo after memory retrieval
Number of subjects: 61
Study: 28024952

Group type: EXPERIMENTAL
Intervention: Prime-boost EVD vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Real-time dynamic modelling
Number of subjects: 0
Study: 27228986

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 51523
Study: 25142791

Group type: EXPERIMENTAL
Intervention: RAMP-DM
Number of subjects: 1248

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1248
Study: 21950726

Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/d
Number of subjects: 30
Study: 20630497

Group type: EXPERIMENTAL
Intervention: Saccharated chewing gum
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum
Number of subjects: 449

Group type: COMPARATOR
Intervention: No chewing gum
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum (second experiment)
Number of subjects: 449

Group type: COMPARATOR
Intervention: No chewing gum (second experiment)
Number of subjects: 449
Study: 17694386

Group type: EXPERIMENTAL
Intervention: Daily low dose plasma exchange
Number of subjects: 33

Group type: COMPARATOR
Intervention: Alternate day plasma exchange
Number of subjects: 33
Study: 15780697

Group type: EXPERIMENTAL
Intervention: Sertraline treatment (not specified dosage or duration)
Number of subjects: 276
Study: 12410505

Group type: EXPERIMENTAL
Intervention: Percutaneous metallic commissurotome (PMC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Inoue balloon mitral valvuloplasty (BMV)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cost comparison
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bilateral commissural splitting
Number of subjects: 80
Study: 9446376

Group type: EXPERIMENTAL
Intervention: Modified Sugiura (Hirashima) procedure
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Late postoperative period (after Hirashima procedure)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (20 healthy volunteers)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Portal vein thrombosis
Number of subjects: 104
Study: 7942937

Group type: EXPERIMENTAL
Intervention: Intermittent very-low-calorie diet (VLCD) of 400 to 500 kcal per day for 12 weeks, alternating with a balanced low-calorie diet (LCD) of 1,000 to 1,000 kcal per day throughout the year-long treatment.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Balanced low-calorie diet (LCD) of 1,000 to 1,000 kcal per day throughout the year-long treatment.
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both groups (VLCD and LCD)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Intermittent VLCD
Number of subjects: 93
Study: 2897388

Group type: EXPERIMENTAL
Intervention: loratadine, 40 mg once daily
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: terfenadine, 60 mg twice daily
Number of subjects: 280

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 280
Study: 30100375

Group type: EXPERIMENTAL
Intervention: Mogamulizumab (1.0 mg/kg intravenously weekly for the first 28-day cycle, then on days 1 and 15 of subsequent cycles)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Vorinostat (400 mg daily)
Number of subjects: 372
Study: 26477659

Group type: EXPERIMENTAL
Intervention: Experimental group (N=33)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Active control group (N=23)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Time spent studying
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Baseline memory performance
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Short-term memory task performance
Number of subjects: 56
Study: 24815533

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg QD
Number of subjects: 463

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg QD
Number of subjects: 463

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study: 22205424

Group type: EXPERIMENTAL
Intervention: Exposure therapy for flight phobia (specific dosage and duration not mentioned)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Exposure therapy for flight phobia
Number of subjects: 45
Study: 20650798

Group type: EXPERIMENTAL
Intervention: Hand-use ProTaper instruments
Number of subjects: 203

Group type: COMPARATOR
Intervention: Standard stainless steel K-file
Number of subjects: 203
Study: 18541590

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) supplementation, mean daily dose of 86 microg (3440 IU) adjusted every 2 months based on serum 25(OH)D concentration.
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Computer simulations for optimal daily dose of vitamin D(3).
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Projected dose-response curves for different baseline 25(OH)D concentrations.
Number of subjects: 138
Study: 15777857

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (AA) at lung, shenmen, thalamus and hip points
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham acupuncture (4 non-acupuncture points on the auricular helix)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (AA)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham acupuncture (control)
Number of subjects: 54
Study: 15611418

Group type: EXPERIMENTAL
Intervention: Partial or complete replacement of amalgam fillings in Group A (13 patients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Partial or complete replacement of amalgam fillings in Group B (8 patients)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Partial or complete replacement of amalgam fillings in Group C (2 patients)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control Group D (20 patients) with signs of allergic contact dermatitis
Number of subjects: 80
Study: 11054193

Group type: EXPERIMENTAL
Intervention: High-dose inhaled flunisolide 2 mg/d
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 9089000

Group type: EXPERIMENTAL
Intervention: Test preparation (tablet Krewel)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference preparation 1 (suspension Krewel)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference preparation 2 (tablet Muskel Trancopal)
Number of subjects: 18
Study: 8447567

Group type: EXPERIMENTAL
Intervention: Clorazepate dipotassium 50 mg on the evening before operation and 25 mg on the morning of the operation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Flunitrazepam 1 mg p.o. on the evening before the operation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Clorazepate dipotassium
Number of subjects: 100

Group type: COMPARATOR
Intervention: i.m. premedication with promethazine, pethidine and atropine
Number of subjects: 100
Study: 3082613

Group type: EXPERIMENTAL
Intervention: Thyroid hormone treatment (100 micrograms thyroxin)
Number of subjects: 1973
Study: 3137624

Group type: EXPERIMENTAL
Intervention: Oxazepam 15 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oxazepam 30 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 29307152

Group type: EXPERIMENTAL
Intervention: 10-week core stability training (CST) program
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 69
Study: 28790042

Group type: EXPERIMENTAL
Intervention: Continuous regulation of tracheal cuff pressure using a pneumatic device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent control of tracheal cuff pressure (once every 8 hours)
Number of subjects: 0
Study: 26328636

Group type: EXPERIMENTAL
Intervention: Allopurinol treatment
Number of subjects: 176

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 176
Study: 24037880

Group type: EXPERIMENTAL
Intervention: 1000 IU/d vitamin D₃
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 5000 IU/d vitamin D₃
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 10,000 IU/d vitamin D₃
Number of subjects: 67
Study: 21798556

Group type: EXPERIMENTAL
Intervention: Rapid sequence intubation (RSI) with glycopyrrolate, thiopental, suxamethonium, and remifentanil
Number of subjects: 34

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 34
Study: 19467538

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone (GnRH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ovarian factors
Number of subjects: 0
Study: 16978371

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 14678061

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (n=105)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-intervention education-as-usual control condition (n=95)
Number of subjects: 200
Study: 11382830

Group type: COMPARATOR
Intervention: 0.75% ropivacaine alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine + 1 microg/kg clonidine
Number of subjects: 30
Study: 9243351

Group type: EXPERIMENTAL
Intervention: 0.2 mmol gadolinium/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.35 mmol gadolinium/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.5 mmol gadolinium/kg
Number of subjects: 18
Study: 8299238

Group type: EXPERIMENTAL
Intervention: Soy diet alone (SD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Soy diet plus 5 g/day of fish oil (SD + FO)
Number of subjects: 20
Study: 2834502

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Kabi 2165)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Non-fractionated heparin
Number of subjects: 79
Study: 29649036

Group type: EXPERIMENTAL
Intervention: Baseline alexithymia measured by the 26-item Toronto Alexithymia Scale (TAS-26)
Number of subjects: 5586

Group type: EXPERIMENTAL
Intervention: Adjustment for age, sex, and occupational status
Number of subjects: 5586

Group type: EXPERIMENTAL
Intervention: Adjustment for all covariates, using binary TAS-26 cut-offs or TAS-26 subscores
Number of subjects: 5586
Study: 27287330

Group type: EXPERIMENTAL
Intervention: Advance care planning
Number of subjects: 282

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 282
Study: 25222264

Group type: EXPERIMENTAL
Intervention: Upper-class clothing (business-suit)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower-class clothing (sweatpants)
Number of subjects: 0
Study: 24120213

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 531

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 531
Study: 20598373

Group type: EXPERIMENTAL
Intervention: HEART CAMP intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 42
Study: 19096768

Group type: EXPERIMENTAL
Intervention: Letrozole (5 years' monotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen (5 years' monotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential therapy (2 years tamoxifen followed by 3 years letrozole)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential therapy (2 years letrozole followed by 3 years tamoxifen)
Number of subjects: 0
Study: 16870078

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg tablets
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study: 12662419

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 299

Group type: COMPARATOR
Intervention: Historical controls (untreated)
Number of subjects: 299
Study: 10229430

Group type: EXPERIMENTAL
Intervention: Active nonsteroidal antiinflammatory drug (NSAID)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study: 8709356

Group type: EXPERIMENTAL
Intervention: Single pediatric donor kidneys
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single pediatric donor kidneys with cyclosporine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Adult donor kidneys
Number of subjects: 60
Study: 2010061

Group type: COMPARATOR
Intervention: Choline supplementation (500 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Choline-deficient diet
Number of subjects: 0